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Abstract A 26-year-old woman developed symptoms of
acute toxicity during cyclosporine (CsA) therapy for graft-
versus-host disease prophylaxis. The standard regimen
included CsA in a dose of 1.5 mg/kg (120 mg) every 12 h,
but, as a medication error, she received a high dose of
500 mg of oral CsA. After 2 h, she developed nausea and
vomiting and, subsequently, flushing, chest tightness, tre-
mor and vertigo. Laboratory and clinical examinations
revealed high blood CsA concentrations (1000 ng/mL after
12 h) with a mild increase in blood pressure. Therefore, the
patient was diagnosed with an acute CsA overdose. Before
confirmation of the overdose by measurement of drug
concentrations, the second dose was administered at its
routine time because of uncertainty about the aetiology of
the symptoms. The third dose was withheld, and the patient
was monitored closely for clinical and laboratory presen-
tations until the time when the abnormalities were relieved.
CsA administration was then resumed with the correct
prescription. The patient was discharged with successful
engraftment and normal biochemical laboratory results
after 1 month. Evaluation with the Naranjo assessment
score indicated a probable relationship between the
patient’s symptoms and overdosage with the suspected
drug. Currently, detailed presentations of acute CsA toxi-
city cases due to overdose are limited in the medical
literature. Evaluation of the patient’s medical and labora-
tory records, with cooperation of all responsible clinical
staff, along with a review of the literature, were very
helpful in discovery of the toxicity incident. Vigilance of
health care providers with regard to medication errors and
early detection of toxicity symptoms can decrease CsA-
related morbidity and mortality in the future.
Key Points
The possibility of occurrence of cyclosporine
toxicity should always be kept in mind in
transplantation settings, because cyclosporine has a
narrow therapeutic index, unpredictable
pharmacokinetics and considerable
probability of medication errors.
After administration of high-dose cyclosporine in the
form of an oral formulation, infusion-reaction-like
symptoms can occur. These symptoms are helpful in
early detection of toxicity cases.
Introduction
Cyclosporine (CsA) is one of the most frequently used
medications for immunosuppressive therapy to prevent
graft-versus-host disease (GVHD), which is a life-threat-
ening event for allogeneic haematopoietic stem cell
recipients. The clinical response to CsA can be unpre-
dictable, because of the complicated pharmacokinetics of
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Considering the widespread application of this drug, acci-
dental overdoses and subsequent toxicities are highly
probable, but, unfortunately, there are currently few case
reports of acute CsA overdose in the literature, and only a
small number of them have occurred in the setting of
haematopoietic stem cell transplantation (HSCT). Patients
undergoing HSCT generally have medical problems such
as haematological malignancies or genetic immune disor-
ders. In addition, co-medications used in HSCT are totally
different from those used in solid organ transplantation or
autoimmune disorders. Notably, the conditioning regimen
in HSCT puts the patient at risk of a unique spectrum of
CsA toxicities. Because of different underlying diseases,
concurrent therapies and risk factors, the presentation of
CsA toxicities in HSCT may be very different from those
in other settings.
The aim of this report is to describe a patient with an
iatrogenic CsA overdose in detail and the situation in
which it happened. A literature review of similar cases,
particularly in the setting of HSCT, has also been included
in order to provide more awareness of early detection and
management of such cases.
Case Report
A 26-year-old woman was admitted to an HSCT centre
with acute myeloid leukaemia (AML). She weighed 79 kg
and was 1.56 m tall (ideal body weight 48.8 kg; body mass
index 32.5 kg/m2). She had a history of postpartum fever,
fatigue, anaemia and high C-reactive protein (CRP) levels,
and consequently received a diagnosis of AML with mat-
uration (AML M2). After the first complete remission with
a ‘7 ? 3’ regimen, involving 7 days of cytarabine and
3 days of daunorubicin, with a full-match sibling donor,
she became a candidate for allogeneic HSCT. The condi-
tioning regimen consisted of busulfan from days -6 to -3
and cyclophosphamide on days -2 and -1. GVHD pro-
phylaxis included intravenous CsA 1.5 mg/kg every 12 h
(120 mg per dose) from day -2, and methotrexate 10 mg
on days ?1, ?3, ?6 and ?11. An antibiotic prophylactic
regimen comprised acyclovir, trimethoprim/sulfamethoxa-
zole, fluconazole and ciprofloxacin, started on day -8, all
administered orally. The prescribed ciprofloxacin dosage
was 500 mg twice daily.
On day -3, the patient mistakenly received 500 mg of
CsA as an oral soft gelatin capsule of a lipid micro-emulsion
formulation, which was excessive, considering her ideal
body weight. The patient had no mucositis nor gastroin-
testinal symptoms before that time. After about 2 h, the
patient experienced nausea and vomiting (50 mL). In the
next 16 h, the patient had nausea without another episode of
vomiting, with reluctance regarding oral feeding, but had
normal defaecation (no diarrhoea). The most annoying
symptom described by the patient was a feeling of flushing
and chest tightness from about 3 h after administration until
the patient’s bedtime (15 h later); then gradually it faded
out and disappeared by the end of the first 24 h, with initial
sublingual temperature and respiratory rate elevations of
about 0.5 C and 5 breaths/min, respectively. The patient’s
(systolic/diastolic) blood pressure was around
115/85 mmHg within 4–6 h of the overdosage, showing a
mild increase from baseline (105/70 mmHg), which was
transient. Cardiac markers were normal. An electrocardio-
gram (ECG) was recorded for the patient at the start of the
chest symptoms, repeated every 12 h and checked by a
cardiologist, with no detectable pathological alterations (not
even tachycardia). The third noticeable complaint was
dizziness, which was remembered by the patient after the
vomiting and occurred with the same pattern as the flushing.
On clinical neurological examination, the only findings
were a transient mild upper limb tremor and benign
paroxysmal positional vertigo. Other findings, including
deep tendon reflexes, plantar reflexes, and other sensory-
motor and cranial nerve examinations, were normal.
A complete blood cell count and biochemistry profile
were requested for the patient from the time of the start of
symptoms and after 9 h, then as a 12 h routine schedule.
Some markers, such as CRP, were monitored at longer
intervals, as per our centre’s policies. The patient’s labo-
ratory test values are summarized in Table 1. Because none
of the laboratory results explained the symptoms (they
were generally normal values for the patient), a clinical
pharmacy consultation was requested for possible drug-
related complications after 6 h post-administration.
After a thorough interview with the patient and the
responsible nursing staff who had observed her continu-
ously during this period, and after investigation of her
medical record and medication chart, it was found that the
ciprofloxacin prescription was hardly readable, and the
most probable drug name mistakenly substituted for
‘ciprofloxacin’ was ‘cyclosporine’. After 12 h post-ad-
ministration, a whole-blood sample for measurement of the
CsA concentration was sent for evaluation of hypothetical
trough concentrations. The next morning was day -2 pre-
transplantation, so, despite a recommendation from the
clinical pharmacy service for a CsA stop order until the
CsA concentration results became available (the turn-
around time is about 12–24 h at our centre), 120 mg of
intravenous CsA was administered as per the routine
GVHD prophylaxis schedule because of uncertainty about
the extent of exposure and the low probability of a medi-
cation error; however, another blood sample was sent for
drug concentration measurement just prior to its adminis-
tration. After 4 h, the result for the first sample was
reported as 1000 ng/mL (12 h post-dose). The second
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sample showed a 600 ng/mL CsA concentration at 24 h
after administration of the mistaken dose. Consequently,
another drug concentration measurement was requested
12 h after the first intravenous dose, and the next dose was
withheld. The patient had no flare of symptoms after
administration of the first intravenous dose. After 12 and
24 h of intravenous dosing, the drug concentrations were
410 and 276 ng/mL, respectively, and the patient was
Table 1 Timetable of clinical events in relation to the first and second cyclosporine (CsA) exposures















2 h 3 h 4 h 6 h 12 h 18 h 24 h: day -2
pre-Tx
36 h 48 h: day -
1 pre-Tx
Vital signs
T (C) 37 37.5 37.5 37.2 37.3 37.2 37 37 37
PR (beats/min) 69 72 72 69 69 69 69 69 69
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8.7 8.3 7.5 8 8.7 9.6
RBCC (103/lL)
[3.9–5.7]
4.72 4.6 4.65 4.78 4.7 4.2
BS (mg/dL) 86 102 145 200 162 141
Na (meq/L)
[135–145]
140 141 139 141 136 149
K (meq/L)
[3.5–5]
4.2 4.1 4.2 4.8 4.8 4.2
Ca (mg/dL)
[8.5–10.5]
9.8 – 9.5 9.6 8.8 8.5
Cr (mg/dL)
[0.5–1.3]
0.7 0.7 0.7 0.7 0.7 0.7
CRP (mg/L)
[\10]
1.5 – – 1.5 – 1.5
ALT (IU/L)
[\40]
24 22 26 25 28 21
Bili-T (mg/dL)
[0.3–2]
0.3 0.4 0.4 0.4 0.3 0.5
Drug conc (ng/
mL) [100–300]
1000 600 410 276
ABG arterial blood gases, ALT alanine aminotransferase, Bili-T total bilirubin, BP blood pressure, BS blood sugar, Ca calcium, CardEnz cardiac
enzymes, Ch chest tightness, conc concentration, Cr serum creatinine, CRP C-reactive protein, Di dizziness, ECG electrocardiogram,
F flushing, GVHD graft-versus-host disease, K potassium, N nausea, Na sodium, neuro neurological, PR pulse rate, pre-Tx pre-transplantation,
RBCC red blood cell count, RR respiratory rate, T temperature, V vomiting, WBCC white blood cell count
a The values listed in [square brackets] are the normal ranges
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symptom free; therefore, routine administration of CsA
120 mg every 12 h was resumed. Afterwards, during the
admission, CsA trough concentrations were checked twice
weekly and, on all occasions, the values were between 200
and 400 ng/mL without any dose modification, except for
one subtherapeutic concentration.
We had the chance to calculate the area under the blood
concentration–time curve (AUC) of CsA and the conse-
quent pharmacokinetic profile of CsA for this patient after
5 days of transition to the oral dosage form on post-
transplantation day ?18 (but unfortunately not during the
intoxication phase). With 250 mg dosing, the AUC, peak
concentration (Cmax), time to reach Cmax (tmax), clearance,
bioavailability and half-life were 3777.5 ngh/mL, 800 ng/
mL, 2 h, 22.5 L/h, 34 % and 3.85 h, respectively.
The patient was discharged with successful engraftment
and normal biochemical laboratory results on day ?31. On
follow-up assessments, she was diagnosed with Glucksberg
grade IV acute GVHD on day ?43, which resulted in
readmission. It was treated successfully with antithymocyte
globulin, methylprednisolone and mycophenolate mofetil.
Methods
To find detailed information about presentations of patients
with CsA overdose in the literature, two accredited scien-
tific databases, PubMed and ScienceDirect, were explored.
Searching PubMed with a (‘cyclosporine’[Majr]) AND
‘toxicity’[Subheading] or ‘drug overdose’[Majr:NoExp]
command, and filtering the results by ‘case reports’, yiel-
ded only 11 and 5 journal articles, respectively. In addition,
the Medical Subject Heading (MeSH) terms ‘cyclosporine’
and ‘medication errors’ were applied to obtain more data
on this issue, but only one article was found. To avoid
overlooking other relevant data, the author also tried using
a (‘Cyclosporine/adverse effects’[Majr] OR ‘Cyclosporine/
poisoning’[Majr] OR ‘Cyclosporine/toxicity’[Majr]) AND
‘Hematopoietic Stem Cell Transplantation’[Majr] search
command, which identified 24 journal articles. The Sci-
enceDirect database was also explored in the ‘advanced
search’ mode with a TITLE-ABSTR-KEY(cyclosporine)
and TITLE-ABSTR-KEY(toxicity) command, which yiel-
ded 925 outputs after 1983—the year in which CsA
received approval from the US Food and Drug Adminis-
tration for use in transplantation. A similar search process
using the terms ‘cyclosporine’ and ‘overdose’ resulted in
855 journal articles. After screening, it was determined that
most of these articles were irrelevant to the scope of this
report. From them, the author chose only 15 cases, on the
basis of their relevance, to build this review on CsA
overdose. Also, some other useful articles were added to
provide further explanation about the reports.
Results and Discussion
The 26-year-old female allogeneic HSCT recipient pre-
sented here mistakenly received a high CsA dose of
500 mg on day -3, instead of a 120 mg intravenous dose,
because the medication prescription was hardly readable
and it was mistaken for another commonly used peri-
transplantation drug with a similar name. This overdosage
caused signs and symptoms of acute adverse reactions and
toxicity. To our knowledge, the demonstrated constellation
of symptoms, as we observed collectively in this case and
in this specific setting, seems to be unique in the medical
literature.
Symptoms
It has been stated frequently that signs and symptoms of
CsA acute adverse reactions or toxicities can present both
with therapeutic doses and with overdoses. However, the
probabilities of some reactions, such as neurotoxicity or
nephrotoxicity, are higher with higher CsA doses and blood
concentrations [1]. As mentioned, our patient’s symptoms
generally were of a gastrointestinal, cardiovascular and
neurological nature. Gastrointestinal intolerance has been
identified as one of the most important CsA side effects,
which is preventable by a ‘go low, go slow’ strategy—
contrary to what happened to our patient [2]. Such com-
plications are commonly reported with oral CsA overdose
and are highly predictable with the first dose—and this was
the first complaint of our patient as well. Sensations of
increased abdominal girth, taste disturbance, anorexia and
mild stomach upset were reported in a multiple sclerosis
case after unintentional overdosing of oral CsA for 8 days.
After discontinuation, the stomach upset was relieved
within a day, but it took 2 weeks for the anorexia and the
sensation of increased abdominal girth [3] to disappear.
Gastroparesis accompanied by nausea, vomiting, bloat-
ing and early satiety have been associated with CsA
administration in bone marrow transplant patients [4]. In
our patient, the onset of the gastrointestinal adverse reac-
tion was consistent with the timing of the estimated Cmax
values in the pharmacokinetic evaluations.
According to our search results, nephrotoxicity is one of
the most frequently reported toxicities of CsA even in acute
circumstances. Besides numerous other aetiologies, CsA
has been implicated as the main cause of renal failure after
HSCT [5]. It has been shown that such damage can be
either reversible or irreversible. Acute kidney injury (cre-
atinine levels increased from 1.1 to 1.4 mg/dL) has been
reported with a CsA overdose, which was corrected about
1 day after withdrawal [3]. Conversely, in a 29-year-old
lung transplant recipient who received a 30 mg/kg/day
dose instead of 3 mg/kg/day by mistake, progressive anuria
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and a subicteric status presented with blood CsA concen-
trations of 4100 ng/mL after 18 h. CsA was stopped but
then resumed after 4 days with detection of 80 ng/mL
blood concentrations. After 10 days, the icterus had dis-
appeared, but renal failure with proteinuria necessitated
continued use of haemodialysis for 6 weeks post-trans-
plantation. The patient’s final creatinine clearance mea-
surement was 18 mL/min, without further improvement,
and he died of endocarditis–septic shock after 14 weeks
[6]. Generally, it could be stated that dose dependency, or
pharmacokinetic allowable of this adversity, is not a con-
stant finding [7, 8]. In our case, an episode of an increase in
serum creatinine was observed around day ?15, but this
was after several days of administration of an aminogly-
coside (amikacin) for a new-onset fever. This makes CsA
overdose a less relevant aetiology. Serum creatinine levels
are routinely measured for this adverse effect at our centre,
as at other centres, but it should be kept in mind that the
possibility of a temporal delay between an initial CsA
insult and the onset of biochemically detectable renal
impairment has been proposed in the literature [9].
Neurotoxicity could be the most prominent acute
symptom observed with CsA overdose [10]. CsA neuro-
toxicity is an annoying—but common—complication in
HSCT, with a wide spectrum of presentations ranging from
tremors, restlessness, dysesthesias of the palms and soles,
paraesthesia, headache, depression, confusion and somno-
lence to Parkinsonism, seizures, altered mental status with
confusion, visual or auditory hallucinations, cortical
blindness, encephalopathy, and coma. Specifically, symp-
toms such as a burning sensation in the mouth, plus feet
and hand hyperaesthesia, have been reported with CsA
overdose, and disappeared 1 week after withdrawal [3].
In the first published case report of a fatal CsA overdose
in an adult, a 51-year-old man with a lung transplant
received a 30 mg/h CsA infusion (instead of 3 mg/h) for
13 h; this resulted in massive cerebral oedema and death.
The first symptoms were bilateral, reactive mydriasis and
absence of cutaneous and tendinous reflexes. Diffuse
cerebral oedema was detected by computed tomography.
Then, through development of severe intracranial hyper-
tension, progressive, non-reactive, bilateral mydriasis and
disappearance of cephalic reflexes also occurred, which
ended in the patient’s death. An important finding of this
report was that the CsA concentration after 7 h of the toxic
infusion was 1256 ng/mL despite recordings of therapeutic
concentrations in routine daily measures, because of
missing Cmax measurements. Just like our patient, this
patient had serum creatinine and hepatic enzyme levels
within normal ranges [11].
In the setting of HSCT, a 34-year-old woman with
myelodysplastic syndrome was described as having a
severe occipital headache immediately after
transplantation, development of acute-onset left-sided
weakness, blurred vision in the right eye, confusion,
incomprehensible speech and seizure activity on the left
side of the body on day ?5, which was related to CsA
neurotoxicity concurrent with therapeutic concentrations
(279 ng/mL) [12]. Acute (early-onset) posterior
encephalopathy has also been reported 36 h after initiation
of CsA infusion for GVHD prophylaxis. The symptoms,
which included a seizure, headache, visual disturbances
and altered mental status, were reversible after CsA with-
drawal [13]. Although these two instances occurred at
therapeutic doses and therapeutic blood concentrations,
they were concomitant with the start and increased con-
centrations of CsA.
Tremor is one of the most alarming and easily
detectable symptoms of CsA toxicity. This presentation is
referred to as ‘toxic transplant tremor’. It generally arises
from severely elevated blood drug concentrations [14]. The
occurrence of a synergistic and deteriorating effect has also
been proposed when CsA is co-administered with other
neurotoxic drugs [15], which is a prevalent occasion in
HSCT conditioning. Our patient had significant neurolog-
ical complications, including tremor and vertigo. Consid-
ering the time proximity of the overdosage and symptoms,
it could be stated that there was a high probability that the
patient presentation’s was caused by CsA. The Naranjo
assessment score was 6, as there have been previous con-
clusive reports on the reaction (?1 point); the adverse
event occurred just after the drug administration
(?2 points); the adverse reaction was improved by with-
holding a dose and decreasing blood concentrations
(?1 point); the same administration did not reoccur for the
patient (0 points); there were alternative possible causes,
such as the conditioning regimen, for the reaction (-
1 point); no placebo was given for checking (0 points);
high blood concentrations were detected (?1 point); the
reaction was undetectable when the dose was decreased
(?1); it was the first exposure for the patient (0 point); and
the adverse event was confirmed by objective laboratory
and clinical examinations (?1 point). If possible, neu-
roimaging studies should be implemented in such instan-
ces, but, because of the subtle clinical picture with rapid
resolution, a clinical decision was made not to break the
patient’s microbial isolation. In many similar observations,
a neurotoxic syndrome has been detected at therapeutic
blood CsA concentrations. Therefore, the presence of a
complicated drug–effect correlation, and a possible role of
numerous intruding factors of the patient’s peri-transplan-
tation status, could be proposed.
CsA can induce a range of cardiovascular effects, from
mild complications to life-threatening adverse effects.
Low-level hypertension is a common finding in CsA
recipients. The occurrence of a transient increase in blood
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pressure through complex mechanisms soon after admin-
istration of CsA has been suggested [16]. Even the coro-
nary and cerebral vascular systems are affected by this
medication, which can result in hazardous outcomes. Also,
direct cardiotoxic effects have been reported with CsA,
such as sinus bradycardia [17] or decreased myocardial
contractile force [18]. In a report of a 61-year-old candidate
for kidney transplantation, inadvertent preoperative
administration of CsA 1000 mg instead of mycophenolate
caused atrial fibrillation. Besides heart rhythm problems,
the patient showed no other abnormality on clinical and
laboratory examinations. Serum CsA concentrations at 1
and 18 h after ingestion were 2438 and 123 ng/mL,
respectively. The ECG was normalized to sinus rhythm
within 1 h. After 24 h, the patient was asymptomatic and
was discharged [19]. Peripheral symptoms such as flushing
of the face and foot swelling have also been reported with
CsA overdose [3].
Interestingly, our patient demonstrated an infusion-re-
action-like syndrome, including flushing and chest tight-
ness with the solid oral product. This could be explained by
acute release of a relatively large amount of the drug into
the bloodstream in the first CsA exposure. Despite previous
observations of similar reactions to intravenous CsA [20],
our report proposes that ‘first’ and ‘high’ exposure would
also be considerable factors for such complications, besides
the dosage form. At our centre, blood pressure is measured
every 6 h in all transplant patients, and on seven consec-
utive occasions (at 4, 6, 12, 18, 24, 30 and 36 h after
dosing), the patient’s blood pressure was higher than at
baseline although this required no therapy, but such a rapid
effect on the cardiovascular system was considerable (and
this finding was inconsistent with an anaphylactoid reac-
tion). According to the above-mentioned studies, perfor-
mance of an ECG and cardiac enzyme monitoring (due to
the chest symptoms of the patient) were rational and rec-
ommendable approaches in such circumstances.
Management
It could be stated that currently there is no globally
accredited guideline for management of CsA overdose
especially in the setting of HSCT, but gathering the sparse
data available from several case reports would be helpful in
achieving a consensus.
In one of the foremost reports of CsA overdose, a
32-year-old kidney transplant recipient received CsA
5000 mg instead of 750 mg. The medication error was
discovered 3 h after ingestion. For management of the
situation, practitioners administered activated charcoal
60 g followed by two 30 g doses every 4 h, with two doses
of magnesium citrate between the charcoal doses. The
plasma drug concentrations were 6700, 675 and 50 ng/mL
at 4, 13 and 47 h after ingestion, respectively. The authors
calculated the CsA apparent half-lives as being much
shorter during charcoal administration [21].
Among the paediatric population, acute overdose with
30 mL (300 mg or 170 mg/kg) of a CsA liquid formulation
has been reported in a 4.5-year-old, 17 kg renal transplant
recipient. Gastric decontamination was undertaken with
ipecac syrup 1 mL/kg 20 min after ingestion, which was
ineffective, and this was repeated 40 min after ingestion,
with successful emesis. One hour after ingestion, activated
charcoal 2 g/kg plus sorbitol was administered in the
emergency department. Measurement of blood CsA con-
centrations after 2 h showed therapeutic concentrations.
After 4 h, the patient was stable without an intoxicated
appearance, so he was discharged and, on medical
instructions, only his next CsA dose was skipped [22].
Besides gastrointestinal decontamination, enhancement
of metabolic elimination with pharmacological enzyme
inducers, such as rifampin, phenytoin or phenobarbital, has
been tried with partial success in some instances [23]. In a
61-year-old man, after administration of 75 mL of CsA
emulsion (7500 mg) via a feeding tube in hospital, the CsA
trough concentration was 3687 ng/mL. When intravenous
phenytoin was started for management of central nervous
system symptoms, the CsA trough concentration decreased
to 171 ng/mL after about 5 days [10].
Also, a 68-year-old man with a transplanted kidney
received a 100-fold oral overdose of CsA, which was dis-
covered within 2 h. Measurements showed plasma CsA
concentrations over 1500 ng/mL. Detoxification therapy
started with intensive gastric lavage followed by suction
and instillation of cholestyramine (4000 mg/bag) but after
8 h, the concentrations were only slightly decreased.
Considering CsA pharmacokinetics and distributive char-
acteristics, whole-blood exchange (WBE) was performed.
For management of CsA-related acute renal failure, con-
tinuous haemofiltration was applied 2 h after WBE. No
considerable change in serum CsA concentrations was
found after WBE. However, plasma CsA concentrations
were rapidly decreased after haemofiltration was started,
falling to 802 ng/mL after 2 h and to 159 ng/mL after 72 h
of continued haemofiltration, respectively. After 5 days of
haemofiltration for anuria, the patient recovered and was
finally discharged. On the basis of pharmacokinetic cal-
culations, the authors raised doubt that the CsA elimination
during haemofiltration could also have been a consequence
of its original elimination rate; therefore, they suggested
hemofiltration only for patients with fully formed renal
impairment [24].
A 55-year-old cardiac transplant patient received a
50-fold oral overdose of CsA (35 mL instead of 0.7 mL),
which was mistakenly administered via an L-tube after the
medication prescription was changed from a solid oral
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form to a syrup dosage form. Only transient deterioration
of renal and hepatic function was noted. Because of the
delay in detection, without gastrointestinal decontamina-
tion, the patient was treated with WBE by the apheresis
method. The blood concentration decreased from 8900 ng/
mL to 285.7 ng/mL after 3 days of the process, with nor-
mal serum creatinine and bilirubin levels [25].
Since our major focus is on HSCT patients, our
review of the literature includes a report in which a
38-year-old female allogeneic transplant recipient, after
an intensive care unit admission and recovery, was pre-
scribed a CsA oral suspension in a dosage of 125 mg
twice daily via a nasogastric tube. However, the patient
received an inadvertent overdose of 5000 mg on the first
administration. The CsA overdose was discovered about
6.5 h after ingestion, and a blood concentration of
1797 ng/mL was recorded. After lavage, 50 g of acti-
vated charcoal and acetylcysteine were administered
about 7.5 and 8 h after the CsA dose, respectively.
Presentation of seizure-like activities was managed with
phenobarbital. Serial magnetic resonance imaging (MRI)
was performed for detection of posterior reversible
encephalopathy syndrome. To help reduce the patient’s
CsA concentrations, both plasma exchange and red blood
cell (RBC) exchange were performed sequentially. In
contrast to the previous report, at first the plasma
exchange was initiated to avoid a delay in procurement
of red cells. The CsA concentration was 782 ng/mL at
the end of the plasma exchange, which was remarkable.
After RBC exchange, the CsA concentration was reduced
to 691 ng/mL. Another plasma exchange was also per-
formed about 23 h after the overdose, after which the
patient’s CsA concentration had reached the upper limit
of the normal therapeutic range. Over the next week, the
patient’s condition stabilized, and MRI showed clearance
of mild white matter changes [26].
As we can see in these chronologically ordered case
reports, therapeutic approaches have evolved a little from
the earlier reports, yet it seems that a straightforward
treatment method with proven efficacy has not been
achieved.
Medication Errors
Acute CsA overdose has been reported more frequently
with oral formulations but more severely with parenteral
administration [27], and this may imply a lack of adequate
outpatient education, besides more frequent use of oral
formulations. In a report from the Swiss Toxicological
Information Centre, iatrogenic errors were incriminated in
about 46 % of overdose cases [28]. As stated in the above-
mentioned case reports, acute CsA intoxication due to
overdoses at medical centres can originate from
‘prescribing errors’ such as illegible handwriting, ‘medi-
cation errors’ including administration of the wrong doses
due to peri-transplantation poly-pharmacy, misreading of
decimals or zeros, miscalculation of the dose from one
formulation to another and, finally, ‘negligence’ of the
involved staff, making errors such as transcription errors in
wards and pharmacies. A major challenge in such fields is
medication error in substitution of solid oral formulations
with liquid formulations [29]. Different amounts of drug
per dose, different bioavailability, and different units of
measurement may cause confusion, especially for admin-
istrators with less experience. In our case, a misreading of
the ciprofloxacin prescription, resulting in erroneous
administration of a ‘ciprofloxacin-sized’ dose of CsA,
resulted in the overdose event. This fact underscores the
roles of poly-pharmacy, prescribing error and medication
errors in overdose cases. It should also be noted that the
drug name ‘cyclosporine’ has different variants, including
‘ciclosporin’, which augments the potential for error
through the similarity of this name to the drug name
‘ciprofloxacin’.
Conclusion
Widespread use of CsA in the transplantation setting
potentially has resulted in numerous cases of overdose and
intoxication, but the number of reports in the medical lit-
erature is very small. In HSCT, the role of correct CsA
dosing is very prominent because of the very high mortality
rate associated with GVHD, the weakened state of patients
after conditioning chemo-radiation without a successful
transplant, and lack of suitable alternative therapeutic
options. Therefore, both prevention and management of
CsA overdose in HSCT are of great importance. These
patients have different underlying diseases, co-medica-
tions, risk factors for toxicity and pharmacokinetic profiles
for CsA, so different presentations of CsA overdose may
occur in the HSCT population.
For prevention of such instances, use of typewritten
prescriptions and labels, double-checking and use of more
experienced staff for administration of peri-transplantation
medications are highly recommended. Also, use of edu-
cational pamphlets or training classes on ‘drug name sim-
ilarities’ would be helpful. At our centre, we have instituted
a new policy that every physician’s prescription should be
double-checked by two nurses (one of them should be the
shift head nurse) before administration. Also, emergency
contact with the physician about any suspicious handwrit-
ing is now obligatory for every drug-administering nurse.
For treatment, according to the above-mentioned
reports, drug withdrawal and gastrointestinal decontami-
nation are the first steps and seem to be the most effective
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strategy for management of CsA overdose. In light of this
fact, early detection of the overdose is very important.
Therefore, knowledge of the major and distinctive signs
and symptoms of acute CsA intoxication in each specific
population is very useful, and this is the main goal of this
report. In our review of the relevant literature, common
presentations of CsA intoxication have been summarized,
but, because of the scarcity of data in the setting of HSCT,
some informative case reports from other settings have also
been included. Although it has been stated that measure-
ment of blood CsA concentrations may have limited value
in management of an acute CsA overdose [27], quantifi-
cation of ‘on the spot’ CsA concentrations, instead of
routine scheduled monitoring, would be very informative
for discovering the extent of the overdose and decision
making about the best therapeutic approach. The ‘golden
hour’ for gastrointestinal decontamination—especially for
induction of emesis or lavage and suction—is short, but
currently no guideline for the best timing is available.
Similar uncertainty exists for implementation of the second
step, including more invasive approaches such as WBE.
Use of enzyme inducers suffers from lack of adequate
experience, unproven efficacy and an increased risk of
unexpected peri-transplantation complications, especially
in HSCT patients with complex pharmacokinetic and
metabolic features. Also, it should be noted that enzyme
induction is a time-consuming process [30], so, in acute
cases, it should not hinder or replace implementation of
more vital measures. Therefore, its place in treatment
protocols should be just as an adjunctive therapy. However,
if the patient has specific co-morbidities, such as seizure or
infection, administration of phenytoin or rifampin,
respectively, could be justified. Considering the pharma-
cokinetic variability of the HSCT population, ‘toxicoki-
netic’ studies on early-detected accidental overdose cases
in this population would be very enlightening for devel-
opment of practice guidelines. In comparison with the
mean values of the pharmacokinetic parameters that have
been calculated for this centre’s patients [unpublished
data], for our intoxicated patient, clearance of the drug was
(fortunately) faster, the half-life was shorter, and the
bioavailability was about half the estimated mean value,
with similar products. This may, to some extent, explain
the short duration and mild presentation of our patient’s
symptoms. On the other hand, these could have been
related to the occurrence of high-grade GVHD in the out-
patient setting when our patient was receiving oral CsA
dosing. In this patient’s toxic state, the drug’s half-life was
over 12 h, whereas the drug’s half-life in a normal situation
is 3.85 h. This finding may imply that CsA pharmacoki-
netics are altered in overdose states.
Besides goal-directed therapies for intoxication—which
generally has shown controversial results—supportive care
for maintaining organ function or for reversal of dysfunc-
tion, such as administration of antioxidants, respiratory
support and dialysis, can have a major role in survival of
overdosed patients. This fact underscores the importance of
frequent monitoring of biomedical and biochemical
markers, as was done in our case.
CsA is a critical agent used extensively for
immunomodulation in the stem cell transplantation setting,
and it has a narrow therapeutic index, so constant aware-
ness on the part of health care providers regarding the
possibility of medication errors and detection of toxicity
symptoms could possibly decrease CsA-related morbidity
and mortality in the future.
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